Consistent with the notion that the presence of CM CD4+ T cells and activated classical monocytes may be required for a successful antitumor response upon anti–PD-1 immunotherapy, we report a greater density of CD8+ T cells and CD20+ B cells in pretreated tumor tissues from patients with durable CBRs than in those from nonresponders. The gene discussed is CD8A; the disease is neoplasm.